Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03144700
Other study ID # ILBS-Cirrhosis-11
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2010
Est. completion date January 2024

Study information

Verified date June 2023
Source Institute of Liver and Biliary Sciences, India
Contact Dr Ankit Bhardwaj, Masters CR
Phone 01146300000
Email bhardwaj.ankit3@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Study Design and Methodology - Study Population:Compensated Cirrhosis - Study Design: An Ambi Prospective Cohort study - Study Period: 2 Years - Sample size: Retrospective- All patients from Jan 2010 to Mar 2017 Prospective- Assuming the incidence of clinical decompensation is 5%/year.With alpha of 5%, power 80% we need to enroll 138 cases. Further assuming 20% drop out 166 cases will be enrolled. - Intervention: This is an observational study. No intervention will be given. Monitoring and assessment: All the routine investigation and clinical information will be collected at 6, 12,18 and 24 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 166
Est. completion date January 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age 18 to 75 years 2. Compensated cirrhosis 3. Biopsy proven cirrhosis or LSM > 12.5 Kpa. Exclusion Criteria: 1. Any current or prior clinical decompesnation (ascites, jaundice, encephalopathy or gastrointestinal hemorrhage). 2. Pregnant Women 3. Hepatocellular Carcinoma 4. Known case of severe cardiopulmonary disease 5. Known case of severe Hepato Pulmonary Syndrome

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
India Institute of Liver and Biliary Sciences New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
Institute of Liver and Biliary Sciences, India

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Development of ascites, jaundice, encephalopathy or gastrointestinal hemorrhage) during the follow up period of 2 yeas 2 years
Secondary Patients with new onset/progression of esophageal varices during the period of 2 years 2 years
Secondary Reduction in portal pressure with >20% from baseline at 6 months 6 months
Secondary Reduction in portal pressure with >20% from baseline at 1 year 1 year
Secondary Reduction in portal pressure with >20% from baseline at 2 year. 2 year
Secondary Survival during the period of 2 years. 2 years
Secondary Number of patients develop hepatocellular carcinoma (HCC) during follow up period 2 years. 2 years
Secondary Number of patients develop Pulmonary Syndrome (HPS) during follow up period of 2 years. 2 years
Secondary Number of patients develop Minimal Hepatic Encephalopathy (MHE) during follow up period of 2 years. 2 years
Secondary Number of patients develop Hypersplenism during follow up period of 2 years. 2 years
Secondary Number of patients develop Hepatic osteodystrophy during follow up period of 2 years. 2 years
See also
  Status Clinical Trial Phase
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Completed NCT02219503 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Phase 3
Recruiting NCT04950764 - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Phase 1
Completed NCT05485714 - Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis
Enrolling by invitation NCT04160897 - Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Completed NCT01704755 - A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis Phase 3
Completed NCT01409356 - Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis Phase 2
Terminated NCT04060147 - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Phase 1
Active, not recruiting NCT03749954 - Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Cirrhosis
Completed NCT01995071 - A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) Phase 2
Not yet recruiting NCT02732405 - Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis Phase 3
Completed NCT04210245 - Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Phase 2
Completed NCT05367596 - OPTIMIzing muScle Preservation in paTients wIth Cirrhosis N/A
Recruiting NCT03990753 - Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)
Completed NCT00190385 - Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis Phase 3
Recruiting NCT04196998 - Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis N/A
Completed NCT02642432 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis Phase 3
Completed NCT03656068 - An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis Phase 2
Not yet recruiting NCT05357599 - The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis N/A
Not yet recruiting NCT06147518 - To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis N/A